Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa
Objective: Assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on the motor states of people with Parkinson’s disease (PD) across 24 hours via…Increase eye blink rate as a motor fluctuation in levodopa-Induced dyskinesia in parkinson’s disease a forgotten indicator of motor fluctuations a case report
Objective: To recognize the increase eye blink rate (EBR) as a potential motor fluctuation (MF) in a PD patient undergoing levodopa treatment Background: A normal…Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study
Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…Efficacy of Rifaximin as an Adjunct Treatment for Levodopa induced dyskinesia: Preliminary Results
Objective: To evaluate the efficacy of rifaximin as an adjunct treatment for LID (levodopa induced dyskinesia) in patients with PD through a randomized, double-blind, placebo-controlled…Efficacy of ND0612 in Patients at Different Stages of Disease Severity: Subgroup-Analyses From a Randomized, Active-Controlled Study in People With Parkinson’s Disease Experiencing Motor Fluctuations
Objective: To evaluate the efficacy of investigational ND0612 in reducing motor fluctuations in patients with Parkinson’s disease (PD) at different stages of disease and/or symptom…The effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Objective: To investigate the effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia (LID) in a rat model of Parkinson’s disease (PD), we analyzed abnormal involuntary movements (AIMs)…Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease
Objective: To assess the longitudinal effect of continuous subcutaneous foslevodopa/foscarbidopa infusion therapy on dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score…Assessing the potential association of rs2298383 in ADORA2A as a predictor of Levodopa-Induced Dyskinesia in Latin American Parkinson’s Disease patients
Objective: To analyze the association between ADORA2A-rs2298383 and levodopa induced dyskinesias (LID) in a cohort of Latin American Parkinson’s disease patients. Background: Previous evidence has…Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease
Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…Does COMT Play a Role in Parkinson’s Disease Susceptibility Across Diverse Ancestral Populations?
Objective: To investigate the relationship between COMT genetic variants and PD risk across diverse ancestries. Background: The enzyme catechol-O-methyltransferase (COMT; OMIM:116790) plays a crucial role…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 44
- Next Page »